Neutralizing IFN-γ autoantibodies are rare and pathogenic in HLA-DRB1*15:02 or 16:02 individuals
BACKGROUNDWeakly virulent environmental mycobacteria (EM) can cause severe disease in HLA-DRB1*15:02 or 16:02 adults harboring neutralizing anti-IFN-γ autoantibodies (nAIGAs). The overall prevalence of nAIGAs in the general population is unknown, as are the penetrance of nAIGAs in HLA-DRB1*15:02 or 16:02 individuals and the proportion of patients with unexplained, adult-onset EM infections carrying nAIGAs.METHODSThis study analyzed the detection and neutralization of anti-IFN-γ autoantibodies (auto-Abs) from 8,430 healthy individuals of the general population, 257 HLA-DRB1*15:02 or 16:02 carriers, 1,063 patients with autoimmune disease, and 497 patients with unexplained severe disease due to EM.RESULTSWe found that anti-IFN-γ auto-Abs detected in 4,148 of 8,430 healthy individuals (49.2%) from the general population of an unknown HLA-DRB1 genotype were not neutralizing. Moreover, we did not find nAIGAs in 257 individuals carrying HLA-DRB1* 15:02 or 16:02. Additionally, nAIGAs were absent in 1,063 patients with an autoimmune disease. Finally, 7 of 497 patients (1.4%) with unexplained severe disease due to EM harbored nAIGAs.CONCLUSIONThese findings suggest that nAIGAs are isolated and that their penetrance in HLA-DRB1*15:02 or 16:02 individuals is low, implying that they may be triggered by rare germline or somatic variants. In contrast, the risk of mycobacterial disease in patients with nAIGAs is high, confirming that these nAIGAs are the cause of EM disease.FUNDINGThe Laboratory of Human Genetics of Infectious Diseases is supported by the Howard Hughes Medical Institute, the Rockefeller University, the St. Giles Foundation, the National Institutes of Health (NIH) (R01AI095983 and U19AIN1625568), the National Center for Advancing Translational Sciences (NCATS), the NIH Clinical and Translational Science Award (CTSA) program (UL1 TR001866), the French National Research Agency (ANR) under the "Investments for the Future" program (ANR-10-IAHU-01), the Integrative Biology of Emerging Infectious Diseases Laboratory of Excellence (ANR-10-LABX-62-IBEID), ANR-GENMSMD (ANR-16-CE17-0005-01), ANR-MAFMACRO (ANR-22-CE92-0008), ANRSECTZ170784, the French Foundation for Medical Research (FRM) (EQU201903007798), the ANRS-COV05, ANR GENVIR (ANR-20-CE93-003), and ANR AI2D (ANR-22-CE15-0046) projects, the ANR-RHU program (ANR-21-RHUS-08-COVIFERON), the European Union's Horizon 2020 research and innovation program under grant agreement no. 824110 (EASI-genomics), the Square Foundation, Grandir - Fonds de solidarité pour l'enfance, the Fondation du Souffle, the SCOR Corporate Foundation for Science, the Battersea & Bowery Advisory Group, William E. Ford, General Atlantic's Chairman and Chief Executive Officer, Gabriel Caillaux, General Atlantic's Co-President, Managing Director, and Head of business in EMEA, and the General Atlantic Foundation, Institut National de la Santé et de la Recherche Médicale (INSERM) and of Paris Cité University. JR was supported by the INSERM PhD program for doctors of pharmacy (poste d'accueil INSERM). JR and TLV were supported by the Bettencourt-Schueller Foundation and the MD-PhD program of the Imagine Institute. MO was supported by the David Rockefeller Graduate Program, the Funai Foundation for Information Technology (FFIT), the Honjo International Scholarship Foundation (HISF), and the New York Hideyo Noguchi Memorial Society (HNMS).
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2024 |
|---|---|
| Erschienen: |
2024 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:134 |
|---|---|
| Enthalten in: |
The Journal of clinical investigation - 134(2024), 8 vom: 12. März |
| Sprache: |
Englisch |
|---|
| Links: |
|---|
| Themen: |
Autoantibodies |
|---|
| Anmerkungen: |
Date Completed 16.04.2024 Date Revised 16.04.2024 published: Electronic Citation Status MEDLINE |
|---|
| doi: |
10.1172/JCI178263 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM369602072 |
|---|
| LEADER | 01000caa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM369602072 | ||
| 003 | DE-627 | ||
| 005 | 20240416232659.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 240312s2024 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1172/JCI178263 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1377.xml |
| 035 | |a (DE-627)NLM369602072 | ||
| 035 | |a (NLM)38470480 | ||
| 035 | |a (PII)e178263 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Peel, Jessica N |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Neutralizing IFN-γ autoantibodies are rare and pathogenic in HLA-DRB1*15:02 or 16:02 individuals |
| 264 | 1 | |c 2024 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 16.04.2024 | ||
| 500 | |a Date Revised 16.04.2024 | ||
| 500 | |a published: Electronic | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a BACKGROUNDWeakly virulent environmental mycobacteria (EM) can cause severe disease in HLA-DRB1*15:02 or 16:02 adults harboring neutralizing anti-IFN-γ autoantibodies (nAIGAs). The overall prevalence of nAIGAs in the general population is unknown, as are the penetrance of nAIGAs in HLA-DRB1*15:02 or 16:02 individuals and the proportion of patients with unexplained, adult-onset EM infections carrying nAIGAs.METHODSThis study analyzed the detection and neutralization of anti-IFN-γ autoantibodies (auto-Abs) from 8,430 healthy individuals of the general population, 257 HLA-DRB1*15:02 or 16:02 carriers, 1,063 patients with autoimmune disease, and 497 patients with unexplained severe disease due to EM.RESULTSWe found that anti-IFN-γ auto-Abs detected in 4,148 of 8,430 healthy individuals (49.2%) from the general population of an unknown HLA-DRB1 genotype were not neutralizing. Moreover, we did not find nAIGAs in 257 individuals carrying HLA-DRB1* 15:02 or 16:02. Additionally, nAIGAs were absent in 1,063 patients with an autoimmune disease. Finally, 7 of 497 patients (1.4%) with unexplained severe disease due to EM harbored nAIGAs.CONCLUSIONThese findings suggest that nAIGAs are isolated and that their penetrance in HLA-DRB1*15:02 or 16:02 individuals is low, implying that they may be triggered by rare germline or somatic variants. In contrast, the risk of mycobacterial disease in patients with nAIGAs is high, confirming that these nAIGAs are the cause of EM disease.FUNDINGThe Laboratory of Human Genetics of Infectious Diseases is supported by the Howard Hughes Medical Institute, the Rockefeller University, the St. Giles Foundation, the National Institutes of Health (NIH) (R01AI095983 and U19AIN1625568), the National Center for Advancing Translational Sciences (NCATS), the NIH Clinical and Translational Science Award (CTSA) program (UL1 TR001866), the French National Research Agency (ANR) under the "Investments for the Future" program (ANR-10-IAHU-01), the Integrative Biology of Emerging Infectious Diseases Laboratory of Excellence (ANR-10-LABX-62-IBEID), ANR-GENMSMD (ANR-16-CE17-0005-01), ANR-MAFMACRO (ANR-22-CE92-0008), ANRSECTZ170784, the French Foundation for Medical Research (FRM) (EQU201903007798), the ANRS-COV05, ANR GENVIR (ANR-20-CE93-003), and ANR AI2D (ANR-22-CE15-0046) projects, the ANR-RHU program (ANR-21-RHUS-08-COVIFERON), the European Union's Horizon 2020 research and innovation program under grant agreement no. 824110 (EASI-genomics), the Square Foundation, Grandir - Fonds de solidarité pour l'enfance, the Fondation du Souffle, the SCOR Corporate Foundation for Science, the Battersea & Bowery Advisory Group, William E. Ford, General Atlantic's Chairman and Chief Executive Officer, Gabriel Caillaux, General Atlantic's Co-President, Managing Director, and Head of business in EMEA, and the General Atlantic Foundation, Institut National de la Santé et de la Recherche Médicale (INSERM) and of Paris Cité University. JR was supported by the INSERM PhD program for doctors of pharmacy (poste d'accueil INSERM). JR and TLV were supported by the Bettencourt-Schueller Foundation and the MD-PhD program of the Imagine Institute. MO was supported by the David Rockefeller Graduate Program, the Funai Foundation for Information Technology (FFIT), the Honjo International Scholarship Foundation (HISF), and the New York Hideyo Noguchi Memorial Society (HNMS) | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a Autoimmune diseases | |
| 650 | 4 | |a Cytokines | |
| 650 | 4 | |a Genetics | |
| 650 | 4 | |a Immunology | |
| 650 | 7 | |a HLA-DRB1 Chains |2 NLM | |
| 650 | 7 | |a Autoantibodies |2 NLM | |
| 700 | 1 | |a Yang, Rui |e verfasserin |4 aut | |
| 700 | 1 | |a Le Voyer, Tom |e verfasserin |4 aut | |
| 700 | 1 | |a Gervais, Adrian |e verfasserin |4 aut | |
| 700 | 1 | |a Rosain, Jérémie |e verfasserin |4 aut | |
| 700 | 1 | |a Bastard, Paul |e verfasserin |4 aut | |
| 700 | 1 | |a Behere, Anish |e verfasserin |4 aut | |
| 700 | 1 | |a Cederholm, Axel |e verfasserin |4 aut | |
| 700 | 1 | |a Bodansky, Aaron |e verfasserin |4 aut | |
| 700 | 1 | |a Seeleuthner, Yoann |e verfasserin |4 aut | |
| 700 | 1 | |a Conil, Clément |e verfasserin |4 aut | |
| 700 | 1 | |a Ding, Jing-Ya |e verfasserin |4 aut | |
| 700 | 1 | |a Lei, Wei-Te |e verfasserin |4 aut | |
| 700 | 1 | |a Bizien, Lucy |e verfasserin |4 aut | |
| 700 | 1 | |a Soudee, Camille |e verfasserin |4 aut | |
| 700 | 1 | |a Migaud, Mélanie |e verfasserin |4 aut | |
| 700 | 1 | |a Ogishi, Masato |e verfasserin |4 aut | |
| 700 | 1 | |a Yatim, Ahmad |e verfasserin |4 aut | |
| 700 | 1 | |a Lee, Danyel |e verfasserin |4 aut | |
| 700 | 1 | |a Bohlen, Jonathan |e verfasserin |4 aut | |
| 700 | 1 | |a Perpoint, Thomas |e verfasserin |4 aut | |
| 700 | 1 | |a Perez, Laura |e verfasserin |4 aut | |
| 700 | 1 | |a Messina, Fernando |e verfasserin |4 aut | |
| 700 | 1 | |a Genet, Roxana |e verfasserin |4 aut | |
| 700 | 1 | |a Karkowski, Ludovic |e verfasserin |4 aut | |
| 700 | 1 | |a Blot, Mathieu |e verfasserin |4 aut | |
| 700 | 1 | |a Lafont, Emmanuel |e verfasserin |4 aut | |
| 700 | 1 | |a Toullec, Laurie |e verfasserin |4 aut | |
| 700 | 1 | |a Goulvestre, Claire |e verfasserin |4 aut | |
| 700 | 1 | |a Mehlal-Sedkaoui, Souad |e verfasserin |4 aut | |
| 700 | 1 | |a Sallette, Jérôme |e verfasserin |4 aut | |
| 700 | 1 | |a Martin, Fernando |e verfasserin |4 aut | |
| 700 | 1 | |a Puel, Anne |e verfasserin |4 aut | |
| 700 | 1 | |a Jouanguy, Emmanuelle |e verfasserin |4 aut | |
| 700 | 0 | |a CONSTANCES cohort |e verfasserin |4 aut | |
| 700 | 0 | |a 3C-Dijon Study |e verfasserin |4 aut | |
| 700 | 0 | |a Etablissement du Sang study group |e verfasserin |4 aut | |
| 700 | 1 | |a Anderson, Mark S |e verfasserin |4 aut | |
| 700 | 1 | |a Landegren, Nils |e verfasserin |4 aut | |
| 700 | 1 | |a Tiberghien, Pierre |e verfasserin |4 aut | |
| 700 | 1 | |a Abel, Laurent |e verfasserin |4 aut | |
| 700 | 1 | |a Boisson-Dupuis, Stéphanie |e verfasserin |4 aut | |
| 700 | 1 | |a Bustamante, Jacinta |e verfasserin |4 aut | |
| 700 | 1 | |a Ku, Cheng-Lung |e verfasserin |4 aut | |
| 700 | 1 | |a Casanova, Jean-Laurent |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t The Journal of clinical investigation |d 1924 |g 134(2024), 8 vom: 12. März |w (DE-627)NLM000005487 |x 1558-8238 |7 nnns |
| 773 | 1 | 8 | |g volume:134 |g year:2024 |g number:8 |g day:12 |g month:03 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1172/JCI178263 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 134 |j 2024 |e 8 |b 12 |c 03 | ||